EGFR and metastatic colorectal cancer: This nested case-control study of 2145 patients from a cohort of patients initiating targeted therapy (angiogenesis or epidermal growth factor receptor inhibitors) for metastatic colorectal cancer, found a low incidence of arterial dissections or aneurysms (0.6%) and no association between exposure to angiogenesis inhibitors and the occurrence of these events after adjustment for cardiovascular risk level.